CTIS2023-504084-17-00招募中1 期
A PHASE I/II, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF ALECTINIB IN PEDIATRIC PATIENTS WITH ALK FUSION-POSITIVE SOLID OR CNS TUMORS FOR WHOM PRIOR TREATMENT HAS PROVEN TO BE INEFFECTIVE OR FOR WHOM THERE IS NO SATISFACTORY STANDARD TREATMENT AVAILABLE - GO42286
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 17（—）
- 性别
- All
入选标准
- •Age at study entry <18 years old, Histologically confirmed diagnosis of CNS or solid tumors with documented evidence of ALK gene fusions as assessed centrally through the use of the investigational F1CDx assay or based on pre-existing NGS test results, Participants with prior treatment proven to be ineffective (relapsed or refractory), or for whom there is no satisfactory treatment available, Participants with tumor tissue availability for submission to the Sponsor from active disease, obtained subsequent to last anti-cancer therapy regimen administered and obtained prior to study enrollment (preferred option), or willing to undergo a core or excisional biopsy sample collection prior to enrollment, Adequate performance status (for participants < 16 years old: Lansky Performance Status should be >= 50% and for participants >= 16 years old: Karnofsky Performance Status should be >= 50%), Participants with adequate end-organ function
排除标准
- •Medical history of prior use of ALK inhibitors, diagnosis of Anaplastic Large Cell Lymphoma (ALCL), any gastrointestinal (GI) disorder that may affect absorption of oral medications, organ transplant, recent stem cell infusions (with or without traumatic brain injury), hypersensitivity to any of the additives in the alectinib drug formulation, substance abuse within 12 months prior to screening, congenital bone disorders, bone metabolism alterations or osteopenia (familial or personal history), treatment with investigational therapy 28 days prior to initiation of study drug, Liver disease as evidenced by abnormal levels of ALT or AST and Bilirubin, Abnormal levels of creatinine or glomerular filtration rate (GFR), Co-administration of anti-cancer therapies other than those administered in this study, Active hepatitis B or C virus (HBV, HBC) or known HIV positivity or AIDS-related illness, Infection considered by the investigator to be clinically uncontrolled or of unacceptable risk to the participant upon induction of neutropenia
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants with Anaplastic Lymphoma Kinase (ALK) Fusion-Positive Solid or Central Nervous System (CNS) TumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)ALK fusion-positive extracranial solid or primary CNS tumors who have progressed following prior treatment or who have no satisfactory treatment availableMedDRA version: 21.0Level: LLTClassification code 10028992Term: Neoplasm CNSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004239-25-DEF. Hoffmann-La Roche Ltd42
进行中（未招募）
1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants with Anaplastic Lymphoma Kinase (ALK) Fusion-Positive Solid or Central Nervous System (CNS) TumorsALK fusion-positive extracranial solid or primary CNS tumors who have progressed following prior treatment or who have no satisfactory treatment availableMedDRA version: 21.0Level: LLTClassification code 10028992Term: Neoplasm CNSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004239-25-DKF. Hoffmann-La Roche Ltd42
进行中（未招募）
1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Patients with Anaplastic Lymphoma Kinase (ALK) Fusion-Positive Solid or Central Nervous System (CNS) TumorsALK fusion-positive extracranial solid or primary CNS tumors who have progressed following prior treatment or who have no satisfactory treatment availableMedDRA version: 21.0Level: LLTClassification code 10028992Term: Neoplasm CNSSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2020-004239-25-FRF. Hoffmann-La Roche Ltd42
进行中（未招募）
1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Patients with Anaplastic Lymphoma Kinase (ALK) Fusion-Positive Solid or Central Nervous System (CNS) TumorsALK fusion-positive extracranial solid or primary CNS tumors who have progressed following prior treatment or who have no satisfactory treatment availableMedDRA version: 21.0Level: LLTClassification code 10028992Term: Neoplasm CNSSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2020-004239-25-ITF. HOFFMANN - LA ROCHE LTD.42
进行中（未招募）
不适用
OPEN-LABEL, MULTICENTRE, PHASE 2 STUDY EVALUATING THE UTILITY OF 123I-nIBG SCINTIGRAPHYFOR ASSESSING ARRHYTHMIC RISK AS COMPARED TO ELECTROPHYSIOLOGY TESTING IN SUBJECTS WITH LEFT VENTRICULAR DYSFUNCTIOCARDIOVASULAR ASSESSING OF ARRHYTHMIC RISCK IN SUBBIECTS WITH LEFT VENTRICULAR DYSFUNCTIOEUCTR2004-000742-21-ITAMERSHAM HEALTH100